Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Gabriel

Showing results (331-340 of 459) with videos related to

Pageof 46
Sort By:
Nature Reviews. Cardiology|January 23, 2026
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapiesMattia Galli, Antonio Abbate, Marc P Bonaca, et al.
Journal of the American College of Cardiology|July 25, 2009
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trialSanjit S Jolly, David P Faxon, Keith A A Fox, et al.
Circulation|May 2, 2007
Clinical end points in coronary stent trials: a case for standardized definitionsDonald E Cutlip, Stephan Windecker, Roxana Mehran, et al.
Journal of the American Heart Association|May 16, 2020
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 TrialRemo H M Furtado, Ramkumar V Venkateswaran, Jose C Nicolau, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|September 20, 2022
The Association Between Midlife Leisure-Time Physical Activity and Hearing Loss in Late Life in the Atherosclerosis Risk in Communities StudyPablo Martinez-Amezcua, Emmanuel Garcia Morales, Kelley P Gabriel, et al.
Critical Pathways in Cardiology|August 31, 2010
Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosisWilliam E Boden, Gregory S Cherr, Kim A Eagle, et al.
American Heart Journal|March 8, 2017
Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialB Daan Westenbrink, Marco Alings, Christopher B Granger, et al.
European Heart Journal|August 4, 2007
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trialThomas H Wang, Deepak L Bhatt, Keith A A Fox, et al.
Heart (British Cardiac Society)|September 28, 2011
Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registryP Gabriel Steg, Samir Alam, Chern-En Chiang, et al.
Circulation|October 8, 2008
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular riskJohn W Eikelboom, Graeme J Hankey, Jim Thom, et al.
Pageof 46

Showing results (331-340 of 459) with videos related to

Sort By:
Pageof 46
Nature Reviews. Cardiology|January 23, 2026
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapiesMattia Galli, Antonio Abbate, Marc P Bonaca, et al.
Journal of the American College of Cardiology|July 25, 2009
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trialSanjit S Jolly, David P Faxon, Keith A A Fox, et al.
Circulation|May 2, 2007
Clinical end points in coronary stent trials: a case for standardized definitionsDonald E Cutlip, Stephan Windecker, Roxana Mehran, et al.
Journal of the American Heart Association|May 16, 2020
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 TrialRemo H M Furtado, Ramkumar V Venkateswaran, Jose C Nicolau, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|September 20, 2022
The Association Between Midlife Leisure-Time Physical Activity and Hearing Loss in Late Life in the Atherosclerosis Risk in Communities StudyPablo Martinez-Amezcua, Emmanuel Garcia Morales, Kelley P Gabriel, et al.
Critical Pathways in Cardiology|August 31, 2010
Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosisWilliam E Boden, Gregory S Cherr, Kim A Eagle, et al.
American Heart Journal|March 8, 2017
Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialB Daan Westenbrink, Marco Alings, Christopher B Granger, et al.
European Heart Journal|August 4, 2007
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trialThomas H Wang, Deepak L Bhatt, Keith A A Fox, et al.
Heart (British Cardiac Society)|September 28, 2011
Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registryP Gabriel Steg, Samir Alam, Chern-En Chiang, et al.
Circulation|October 8, 2008
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular riskJohn W Eikelboom, Graeme J Hankey, Jim Thom, et al.
Pageof 46